Galmed Pharmaceuticals
GLMD
13 hedge funds and large institutions have $286K invested in Galmed Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 3 closing their positions.
0.14% less ownership
Funds ownership: 1.51% → 1.38% (-0.14%)
19% less funds holding
Funds holding: 16 → 13 (-3)
33% less capital invested
Capital invested by funds: $429K → $286K (-$143K)
50% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 4
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$57.5K |
| 2 |
CH
CVI Holdings
Wilmington,
Delaware
|
+$7.88K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Walleye Capital
New York
|
-$53.3K |
| 2 |
VF
Virtu Financial
New York
|
-$18K |
| 3 |
Millennium Management
New York
|
-$12.5K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$11.6K |
| 5 |
Two Sigma Investments
New York
|
-$2.86K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CH
1
CVI Holdings
Wilmington,
Delaware
| $123K | +$7.88K | +1,655 | +8% |
|
|
2
Morgan Stanley
New York
| $75K | +$57.5K | +12,076 | +724% |
|
|
3
Walleye Capital
New York
| $52.5K | -$53.3K | -11,197 | -54% |
|
4
Two Sigma Advisers
New York
| $20.2K | -$2.46K | -516 | -12% |
|
|
5
Two Sigma Investments
New York
| $10.7K | -$2.86K | -600 | -23% |
|
|
6
Citadel Advisors
Miami,
Florida
| $5.12K | -$11.6K | -2,434 | -72% |
|
7
Wells Fargo
San Francisco,
California
| $93 | – | – | – |
|
|
FDCDDQ
8
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
| $76 | – | – | – |
|
9
Osaic Holdings
Scottsdale,
Arizona
| $24 | – | – | – |
|
|
BCM
10
Bourgeon Capital Management
Darien,
Connecticut
| $16 | – | – | – |
|
|
AF
11
Allworth Financial
Folsom,
California
| $8 | – | – | – |
|
|
EWP
12
Elevation Wealth Partners
Santa Rosa,
California
| $5 | – | – | – |
|
|
VF
13
Virtu Financial
New York
| – | -$18K | -2,467 | Closed |
|
|
14
Millennium Management
New York
| – | -$12.5K | -1,678 | Closed |
|
15
UBS Group
Zurich,
Switzerland
| – | -$17 | -2 | Closed |
|
GLMD Hedge Fund Activity: Q4 2023 in Review
13 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Galmed Pharmaceuticals (GLMD) for Q4 2023, worth a combined $286K — down 33% from $429K a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of GLMD and 0 opened new positions — a net loss of 3 holders — while 4 trimmed existing stakes and 2 added.
The largest buyer was Morgan Stanley, adding an estimated $57.5K. The largest seller was Walleye Capital, cutting an estimated $53.3K.
- 13 institutional investors held Galmed Pharmaceuticals (GLMD) as of Q4 2023, down from 16 in Q3 2023.
- Funds reported $286K of Galmed Pharmaceuticals stock for Q4 2023, down 33% quarter-over-quarter.
- 0 funds opened new Galmed Pharmaceuticals positions in Q4 2023 and 3 closed out, a net change of -3 holders.
- The largest Galmed Pharmaceuticals buyer in Q4 2023 was Morgan Stanley, an estimated $57.5K added.
- The largest Galmed Pharmaceuticals seller in Q4 2023 was Walleye Capital, an estimated $53.3K sold.
Based on aggregated 13F filings for Q4 2023.